Company intelligence / Profile preview

Mole Bioscience

Taizhou, Jiangsu, Chinaen.molechina.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mole Bioscience has developed and commercialized a range of molecular diagnostic reagents and rapid tests for infectious diseases. Their products have obtained CE marking, ISO 13485 certification, UKCA certification and other international regulatory approvals. The company leverages advanced PCR technology as well as antigen/antibody detection methods for accurate diagnosis of respiratory pathogens including SARS-CoV‑2.

Therapeutic areas: Infectious Diseases
Modalities: Multiplex fluorescence quantitative PCRHigh-throughput sequencingAntigen/antibody detection technologies
Industry: Molecular Diagnostics

Partnerships

Zhejiang University (R&D collaboration)

Beyond the preview

Go deeper on Mole Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mole Bioscience.

Explore the full profile